Introduction
============

Anemia is a major cause of morbidity and mortality among chronic kidney disease (CKD) patients.[@b1-ijnrd-12-019] It is defined as a low level of hemoglobin (Hb), \<12 g/dL in females and \<13 g/dL in males among CKD patients.[@b2-ijnrd-12-019] About 75% of CKD patients were reported[@b3-ijnrd-12-019] to be anemic in low- and middle-income countries (LMICs), as compared to a lower anemia prevalence of 22.2% among CKD patients in high-income countries.[@b3-ijnrd-12-019] Anemia occurs early in the course of kidney disease and may worsen and become intractable with declining kidney function.[@b1-ijnrd-12-019]--[@b4-ijnrd-12-019]

Although the development of anemia in CKD patients is mainly due to an absolute or relative deficiency of erythropoietin, other possible causes of anemia include blood loss, decreased half-life of red blood cells, iron deficiency, inflammation, nutritional deficiency (due to an inadequate diet and defective iron absorption), and accumulation of uremic toxins that inhibit erythropoiesis.[@b4-ijnrd-12-019],[@b5-ijnrd-12-019] Iron deficiency anemia (IDA) is also a major cause of anemia in CKD. Several causes of IDA in CKD patients include blood loss (from frequent laboratory testing, occult gastrointestinal bleeding, access bleeding), decreased duodenal iron absorption (resulting from inflammation), interference with iron absorption (resulting from medications such as gastric acid inhibitors, phosphate binders).[@b6-ijnrd-12-019]

Some of the adverse clinical outcomes of anemia in CKD patients include sleep disturbance, exercise intolerance, and increased mortality.[@b7-ijnrd-12-019] Hence, some studies have shown that early identification and prompt treatment of anemia through near normalization of hemoglobin and iron levels in CKD patients is associated with slower progression to end-stage kidney disease, and reduced cardiovascular morbidity and mortality as reported in the Cardiovascular Risk Reduction by Early Treatment with Epoietin Beta (CREATE) trial.[@b8-ijnrd-12-019],[@b9-ijnrd-12-019]

Anemia in CKD patients is the product of a complex interplay between patient-specific attributes, CKD stage, treatment modalities, socioeconomic and environmental factors. Therefore, it is being advocated that individualized risk-based management of anemia in CKD patients should be promoted because of the multiple factors responsible for the evolution of anemia in them.[@b10-ijnrd-12-019]

Oral iron is usually preferred because of its convenience and low cost. However, its utility is often limited by gastrointestinal side effects, poor absorption, and low efficacy in CKD.[@b11-ijnrd-12-019],[@b12-ijnrd-12-019]

South Africa is a multiethnic country with about 80% of the population being black and most of them likely to be of low socioeconomic status (SES). Annual household income for blacks stood at an average of 92,893 rands (about 7,000 US dollars) compared with 444,446 rands (29,000 US dollars) for whites, according to the Statistics South Africa's Living Condition Survey. Furthermore, the median monthly earnings of white (R9,500), Indian/Asian (R6,000), mixed race (R2,652), and black (R2,167) South Africans showed a marked ethnic disparity in SES.[@b13-ijnrd-12-019]--[@b16-ijnrd-12-019] Hence, socioeconomic circumstances among CKD patients may impact on the prevalence and outcomes of anemia in them.[@b17-ijnrd-12-019],[@b18-ijnrd-12-019] However, little is currently known of the interactions of various predictors of anemia among the different ethnic groups of CKD patients who are yet to commence dialysis in South Africa. Therefore, we aimed to assess the overall and ethnic prevalence of IDA, CKD stage-specific prevalence and possible predictors of anemia among the predialysis CKD patients in Johannesburg.[@b17-ijnrd-12-019],[@b18-ijnrd-12-019]

Patients and methods
====================

This cross-sectional study was conducted on 353 pre-dialysis CKD patients from June 1 to December 31, 2016. The study population comprised patients attending the renal outpatient clinic of Charlotte Maxeke Academic Hospital, Johannesburg. All consecutively consenting pre-dialysis CKD participants (\>18 years of age) were recruited into the study. Patients with active bleeding (such as upper gastrointestinal bleeding), infection, inflammation, blood transfusion within 3 months of enrolment, on oral iron therapy (within 2 weeks of enrolment), treatment with erythropoietin stimulating agents (ESAs) within 4 weeks of enrolment, active malignancy, human immunodeficiency virus infection, use of immunosuppressive drugs, and patients with known hemoglobinopathies were excluded from the study.

Sociodemographic characteristics were obtained using a proforma. Employment status and educational level were used as proxy for SES in this study.[@b19-ijnrd-12-019] In addition, weight, height, and blood pressure were measured using a stadiometer and mercury sphygmomanometer, respectively. Hypertension was defined as two or more blood pressure readings \>140/90 mmHg as defined by JNC 7.[@b20-ijnrd-12-019] Blood samples were collected for serum electrolytes and hematological parameters. Biochemical iron status, serum iron, total iron-binding capacity (TIBC), and serum ferritin were measured. Serum iron was determined by ferrozine calometric method, TIBC by colorimetric chromazurol dye binding method using ADVIA 1800 (Siemen Medical Solutions Diagnostic, Tarrytown, NY, USA), and serum ferritin was determined by using two-site chemiluminescent immunometric assay by IMMULITE^®^2000 system (Siemens Medical Solutions Diagnostics). Transferrin saturation was calculated by the formula: serum iron/TIBC ×100. Complete blood counts were obtained after processing the blood samples using Siemens ADVIA 2120, Technion H3 RTX, and RTC system analyzer (Siemens Medical Solutions Diagnostics).

Participants were classified as anemic based on a hemoglobin level of \<13 g/dL in men and \<12 g/dL in women. Mild anemia was defined as Hb \>11 g/dL, moderate as Hb of 9--11 g/dL, and severe anemia as Hb of \<9 g/dL.[@b21-ijnrd-12-019] We defined iron deficiency as serum ferritin \<100 µg/L or ferritin 100--300 µg/L and transferrin saturation (TSAT) \<20%.[@b17-ijnrd-12-019] Glomerular filtration rate (GFR) was determined by the Chronic Kidney Disease Epidemiology Collaboration equation for eGFR;[@b22-ijnrd-12-019] stage I, eGFR \>90 mL/min; stage II, eGFR 60--89 mL/min; stage III, eGFR 30--59 mL/min; stage IV, eGFR 15--29 mL/min; and stage V, eGFR \<15 mL/min.

Ethical approval for the study was obtained from the Human Research Ethics Committee of the University of the Witwatersrand (ethics certificate number: M150929). All the participants provided written informed consent.

Statistical analysis
--------------------

Normally distributed continuous variables were presented as mean ± SD, while non-normally distributed continuous variables were presented as median (interquartile range). Categorical variables were presented as numbers, percentages, and charts. The prevalence of anemia (with 95% CI) among the CKD participants and by sociodemographic factors was estimated. All these were stratified by the four ethnic groups (blacks, whites, mixed race group, and Indians/Asians).

Sociodemographic and clinical parameters were compared between anemic and non-anemic patients using Pearson's chi-square and Student's *t*-test as appropriate.

The relationship between anemia status and the stages of CKD was determined using Pearson's chi-squared test (Fisher's exact test was used when the expected cells were less than 5). Furthermore, the difference in mean levels of hematological parameters by stage of CKD was compared using ANOVA. Post hoc Bonferroni pairwise test was conducted to determine where the statistically significant difference lies. This analysis was conducted for each ethnic group. Univariable logistic regression was conducted for all the explanatory variables with anemia status as the outcome of interest. Variables with *P*-value \<0.2 were added in the backward elimination method to arrive at the final univariable and multivariable model, respectively of the predictors of anemia. CKD stage and ethnicity were the primary explanatory variables. However, age, gender, and history of diabetes mellitus (DM) were added to the model because they were selected a priori. Crude and adjusted ORs and 95% CI were obtained from the multivariable model. Post regression diagnostics was conducted using the Hosmer--Lemeshow goodness of fit test, and the discriminatory value of the model for predicting anemia status in the CKD participants was determined based on the area under the curve of the receiver operator characteristics (ROC) curve. Two-tailed test of hypothesis was assumed. The statistically significant level was set at 95% CI (or *P*-value \<0.05). Data were analyzed using Stata version 14 (StataCorp LP, College Station, TX, USA).

Results
=======

Of the 379 eligible participants, 26 declined to participate in the study; 353 were therefore enrolled into the study. The mean age of the participants was 55.3±15.0 years. The majority of participants were blacks (n=258/353, 73.1%), followed by whites (n=52/353, 14.7%), Indians/Asians (n=22/353, 6.2%), and mixed race (n=21/353, 6.0%).

The overall prevalence of anemia was 43.1% (95% CI: 38.1%--48.4%; [Figure 1](#f1-ijnrd-12-019){ref-type="fig"}). The Indian/Asian population had the lowest prevalence of anemia, while the blacks had the highest. Prevalence of anemia among blacks, mixed race, whites, and Indian/Asians was: 46.9% (95% CI: 40.8--53.0), 45% (95% CI: 23.8--68.2), 34.6% (95% CI: 22.7--48.9), and 18.2% (95% CI: 6.4--41.9), respectively. Furthermore, the prevalence of IDA among blacks, whites, mixed race, and Indians/Asians was 35.3% (95% CI: 29.6%--41.3%), 23.1% (95% CI: 13.3%--36.9%), 14.3% (95% CI: 4.2%--38.7%), and 9.1% (95% CI: 2.0%--3.3%), respectively.

The majority (79.0%) of the participants were in late stages of CKD (stages III--V) ([Table 1](#t1-ijnrd-12-019){ref-type="table"}). About 44.6% (91/204) of hypertensive participants were anemic while 40.4% (38/94) of diabetic participants were anemic ([Figure 2](#f2-ijnrd-12-019){ref-type="fig"}). The mean C-reactive protein (CRP) level of the anemic participants was higher than that of non-anemic patients (33.6±4.32 vs 14.80±1.7, *P*-value \<0.001).

There were no significant ethnic differences in the clinical characteristics among the anemic participants. However, blacks had the lowest mean age at recruitment (52.40±14.0 years, *P*-value \<0.001; [Table 1](#t1-ijnrd-12-019){ref-type="table"}). None of the 92 smokers in the cohort had anemia ([Table 1](#t1-ijnrd-12-019){ref-type="table"}).

[Table 2](#t2-ijnrd-12-019){ref-type="table"} shows that there was a statistically significant association between the stages of CKD and anemia status (*P*-value \<0.001). The proportion of participants with anemia decreased from 39.1% in CKD stage I to 21.9% in stage IIIa, and then increased to 91.4% among stage V black participants. There was a statistically significant difference in the mean levels of Hb, mean corpuscular hemoglobin, and mean corpuscular volume (MCV) across the stages of CKD ([Table 2](#t2-ijnrd-12-019){ref-type="table"}).

The mean CRP fluctuated between 10±1.5 and 21.9±5.0 mg/L between stage I and stage IIIa and increased from 13 mg/L in stage IIIb to 51.3 mg/L in stage V (*P*-value \<0.0001). Furthermore, the prevalence of inflammation decreased from stage I (26.1%) to stage III (9.4%) and subsequently increased, reaching the highest levels in stage V (86.2%) ([Table 2](#t2-ijnrd-12-019){ref-type="table"}). The post hoc Bonferroni analysis is shown in [Table 3](#t3-ijnrd-12-019){ref-type="table"}.

Among the white ethnic group, Hb levels were statistically different across the stages of CKD (*P*-value \<0.0001; [Table 4](#t4-ijnrd-12-019){ref-type="table"}). However, there was no statistically significant difference in the parameters among the stages in the mixed and Indian/Asian races ([Tables S1](#SD1-ijnrd-12-019){ref-type="supplementary-material"} and [S2](#SD2-ijnrd-12-019){ref-type="supplementary-material"}).

Furthermore, there was a positive correlation between hemoglobin levels and eGFR (*r*=0.334, *P*-value \<0.0001). There was also a positive correlation between Hb level and eGFR across the ethnic groups ([Table S3](#SD3-ijnrd-12-019){ref-type="supplementary-material"}).

Globally, there was a J-shaped relationship between CKD stage and the odds of anemia as shown in [Figure 3](#f3-ijnrd-12-019){ref-type="fig"}. Thus, the odds of anemia decreased from 1.0 in stage I to 0.17 at stage III and subsequently increased abruptly from stage IV (adj odds ratio \[OR\]: 0.66) to stage V (adj OR: 3.83). Furthermore, there was an 83% less likely chance of anemia among stage III participants as compared to stage I participants (adj OR: 0.17, 95% CI: 0.05--0.54, *P*-value =0.003), while stage V participants had a 3.8-fold increased odds of anemia as compared to stage I participants after correcting for confounding variables ([Table 5](#t5-ijnrd-12-019){ref-type="table"}). In addition, CKD participants with DM had a twofold increased odds of developing anemia as compared to those without DM. However, history of hypertension did not impact on the odds of anemia among the participants. There was no statistically significant difference in the odds of anemia by gender (*P*-value =0.388). There was a 96% lesser odds of anemia among the Indian/Asian as compared to the blacks ([Table 5](#t5-ijnrd-12-019){ref-type="table"}).

Although there was a fivefold increased odds of anemia among participants with inflammation (as defined by CRP levels) on univariable analysis, this relationship did not reach statistical significance after correcting for confounders in the multivariable model. Patients with hypoalbuminaemia had a threefold increased odds for anemia while those with lower TSAT were less likely to develop anemia ([Table 5](#t5-ijnrd-12-019){ref-type="table"}).

Based on the Hosmer--Lemeshow goodness of fit test (*P*-value =0.9939), the final model shows that the model fitted the data. Also, the area under the ROC curve of the final model was 86%, which showed that the final model highly discriminated anemia among the participants.

Discussion
==========

Anemia is a major complication of CKD. It is also a risk factor for cardiovascular disease among CKD patients.[@b23-ijnrd-12-019] While some studies from South Africa reported the prevalence of anemia in the healthy population,[@b24-ijnrd-12-019] the prevalence of anemia in South African CKD patients is largely unknown. In this present study involving a multiethnic CKD population, almost half (43.18%, 95% CI: 38.1%--48.4%) of the study participants had anemia. As expected, our study showed a higher anemia prevalence as compared to the prevalence of 12.5% that was reported among the adult South African population.[@b24-ijnrd-12-019] This prevalence of anemia is lower than previous reports from most LMICs that reported a prevalence of 75%--79% among CKD patients.[@b25-ijnrd-12-019]--[@b28-ijnrd-12-019] A slightly higher anemia prevalence of 58.5% was reported among patients with CKD stages III--V in Catalonia.[@b21-ijnrd-12-019],[@b29-ijnrd-12-019] Furthermore, our study showed that the prevalence of anemia among South African CKD patients was twofold to threefold higher than the prevalence of anemia among CKD patients in the UK and the USA.[@b30-ijnrd-12-019],[@b31-ijnrd-12-019]

In Singapore, a lower prevalence of anemia (35.4%) was reported among CKD patients by Lau et al,[@b32-ijnrd-12-019] while in Nepal, similar to our study, a prevalence of 47.5% was reported.[@b33-ijnrd-12-019] Geographical location (altitude), lifestyle, racial and genetic make-up may have played significant roles in the observed variations in the prevalence of anemia among our cohort of CKD patients as compared to CKD patients from other regions. The relatively lower prevalence of anemia among CKD patients in Johannesburg as compared to other LMICs may be related to the relatively increased level of access to health care services among CKD patients in South Africa. South African CKD patients have access to free medical care as compared to the majority of CKD patients from other developing countries that pay out of pocket for their medical services. The aforementioned suggest the need for global advocacy to design policies that will reduce the cost and burden of CKD on patients and their relatives. This can impact positively on prognostic factors such as anemia and thereby improve outcomes.

There was a marked ethnic variation in the prevalence of anemia in our study population with the black and mixed ethnic groups having a similarly high prevalence (45%--47%), while the whites and Indians/Asians had lower prevalence (18%--35%). This ethnic disparity in prevalence of anemia may be related to the general SES and dietary patterns of the ethnic groups. SES has been shown to be a predictor of nutritional status in several studies.[@b34-ijnrd-12-019],[@b35-ijnrd-12-019] Pathways through which SES may be associated with nutritional status include income, education, and occupation.[@b36-ijnrd-12-019] Some studies conducted in developing counties are in agreement with our findings that low SES is associated with high prevalence of anaemia.[@b37-ijnrd-12-019]--[@b39-ijnrd-12-019] Most of these studies were conducted in developing countries with limited sample size and were not on CKD patients. Our study revealed that almost half of our black cohort had low levels of education. The low educational attainment can be a proxy for low SES among them. The blacks are generally of a lower socioeconomic class mainly because of the deprivation that was suffered during the apartheid era. Moreover, the Indian/Asians' vegetarian lifestyle might increase the rate of anemia among them, which was not a finding in this study; possible explanation could be that most of them may not be on strict vegetarian diet.[@b17-ijnrd-12-019],[@b40-ijnrd-12-019] Our observation also showed that tailored management may be necessary. Thus, in addition to routine CKD care, nutritional support may be more frequently indicated among the blacks and mixed-race South Africans as compared to the whites and Indian/Asians.

Although about four-fifths of our cohort of CKD patients had advanced CKD, almost half of the anemic patients had mild anemia. A similar predominance of mild anemia among CKD patients was also reported in other studies.[@b28-ijnrd-12-019],[@b41-ijnrd-12-019] In contrast to studies from both high-income countries and LMICs, the prevalence of anemia in our cohort did not increase linearly with increasing stages of CKD. Furthermore, we surprisingly found that the odds of anemia were lowest among stages II and III but higher among stages I and V CKD. A study conducted in the Kingdom of Saudi Arabia showed a similar prevalence pattern of anemia among pre-dialysis patients according to the stages of CKD with a prevalence of 42%, 33%, 48%, 71%, and 82%, respectively, among stages I--V CKD participants.[@b28-ijnrd-12-019] The J-shaped pattern of the prevalence of inflammation among CKD stages was similar to the pattern of anemia across stages of CKD in this study, as there was a decreasing prevalence of inflammation (26.1%) in stage I to a nadir of 9.4% in stage III, followed by an abrupt rise in indicators of inflammation up till stage V (86.6%) among the majority of black participants. Furthermore, we found on univariable analysis that there was a fivefold increased odds of anemia among participants with inflammation. This may suggest a link between inflammation and anemia among CKD participants. From the foregoing, although the link between anemia and inflammation across CKD stages is poorly understood, our study further suggests that inflammatory processes may play a role in the development of anemia among CKD patients (and possibly across the stages of CKD) as shown in other studies.[@b42-ijnrd-12-019],[@b43-ijnrd-12-019]

In the present study, the increased odds of anemia in CKD stage V is consistent with the findings from previous studies.[@b27-ijnrd-12-019],[@b28-ijnrd-12-019],[@b44-ijnrd-12-019] For example, Lau et al have shown that in comparison with patients with CKD stage I, stage V CKD patients are more likely to develop anemia (OR 16.8).[@b32-ijnrd-12-019]

Anemia is believed to traditionally worsen with progressive decline in kidney function, as it is believed that erythropoietin production decreases as kidney function worsens.[@b45-ijnrd-12-019] A few hypotheses may be proposed to partly explain the J-shaped pattern of anemia risk among varying stages of CKD patients as observed in our study participants. There may be some unrecognized perturbations that are responsible for this initial improvement in hemoglobin levels as kidney disease worsens from stage I to stage III before the eventual decline in hemoglobin concentrations from stage III to stage V. First, the initial inflammatory process in early stages of CKD may cause hyperstimulation of erythropoietin that then produces higher levels of hemoglobin.[@b4-ijnrd-12-019],[@b46-ijnrd-12-019] This mechanism may not be sustained with continuing deterioration of kidney function during the later stages of CKD, and hepcidin pathways and hypoxia inducible factors may play a role in this mechanism. Second, there might be aggressive management of anemia in the early stages of the disease, or patients may respond to the anemia treatment modalities (such as oral iron therapy and ESA) that are employed in the early stages of the disease, especially at stages I and II. Thus, patients may not respond properly to similar modalities of treatment at the later stages of the disease. Such intractable anemic states at the later stages may be related to poor nutritional status or there may be the need to employ parenteral erythropoietin therapy that may not be readily available for use at earlier stages. Thus, there may be the need to closely monitor anemia in all CKD patients as the disease progresses. Another hypothesis for the pattern of anemia progression with stages of kidney failure may be that there may be some unrecognized mechanisms that support hemoglobin concentration in stages II and III of CKD disease. All the aforementioned hypotheses still need further evaluation. Thus, CKD staging alone may not be wholly appropriate for screening or determination of the risk and severity of anemia among CKD patients.

GFR, gender, ethnicity, iron therapy, and other comorbidities such as DM were identified as risk factors of anemia among CKD patients by other researchers.[@b32-ijnrd-12-019],[@b47-ijnrd-12-019],[@b48-ijnrd-12-019] However, some differences were observed in our study. Contrary to previous studies,[@b31-ijnrd-12-019],[@b48-ijnrd-12-019] we did not find a significant association between gender and development of anemia (*P*-value =0.6). McClellan et al found that female patients had higher odds of developing anemia.[@b31-ijnrd-12-019] Similarly, Fishbane et al[@b78-ijnrd-12-019] reported lower rates of IDA among adult men (57.8%--58.8%) as compared to women (69.9%--72.8%) with CKD stages III--V in the National Health and Nutrition Examination Survey (NHANESII \[1988--1994\] and 1999--2004 surveys).[@b31-ijnrd-12-019],[@b49-ijnrd-12-019]

Our study tends to support the reports of previous researchers[@b3-ijnrd-12-019],[@b50-ijnrd-12-019] that increasing age is an independent risk factor for anemia among CKD patients, as we found that patients who were older than 50 years have double the risk of anemia as compared to younger patients. Thus, the process of aging may greatly contribute to poor outcomes of anemia in CKD patients. Older patients with anemia may also have intractable forms of anemia and should therefore be managed more intensively.

Consistent with previous studies, CKD patients with DM had a threefold increased risk of anemia (*P*=0.007).[@b51-ijnrd-12-019],[@b52-ijnrd-12-019] Thus, a high index of suspicion for anemia should be instituted among diabetic CKD patients to improve the outcomes in them. There is evidence that anemia is more severe and occurs at an earlier stage of kidney disease in patients with diabetes compared with non-diabetic patients;[@b53-ijnrd-12-019],[@b54-ijnrd-12-019] some studies suggest that renal abnormalities, possibly interstitial fibrosis may play a role in the pathophysiology of anemia in diabetes.[@b53-ijnrd-12-019],[@b55-ijnrd-12-019] Less well-known causes of anemia in diabetes may include interrelated mechanisms, such as ultrafiltration, proteinuria, chronic inflammation, damage of interstitial kidney tissue, autonomic nephropathy, uremic toxins, renin-angiotensin system, increased tubular sodium reabsorption, and disorders of erythrocytes have all been implicated in the pathogenic mechanism of anemia in diabetic patients.[@b56-ijnrd-12-019]--[@b58-ijnrd-12-019] In this present study, smoking was not a predictor of anemia, but it was associated with increase in hemoglobin levels; this finding is in agreement with previous studies.[@b59-ijnrd-12-019]--[@b61-ijnrd-12-019] Possible explanation for this finding is that cigarette smoking causes an upward shift of the hemoglobin distribution curve, which reduces the utility of hemoglobin levels to detect anemia; hence, it causes increased hemoglobin concentration, that is likely mediated by exposure to carbon monoxide.[@b60-ijnrd-12-019] Furthermore, hypoalbuminemia was associated with anemia in our study, which is in agreement with the results of earlier studies in CKD and hemodialysis patients.[@b62-ijnrd-12-019],[@b63-ijnrd-12-019] Low serum albumin is used as a marker of inflammation, and the relationship between anemia and inflammation, and malnutrition was shown in several studies.[@b64-ijnrd-12-019],[@b65-ijnrd-12-019]

Similar to previous studies, other predictors of anemia in our study participants include TSAT and hypocalcemia.[@b8-ijnrd-12-019],[@b66-ijnrd-12-019] In this study, hypocalcemia was a predictor of anemia among our cohort of CKD participants. This finding is in agreement with other researchers.[@b67-ijnrd-12-019],[@b68-ijnrd-12-019] Several mechanisms have been postulated to explain this observed relationship. For example, hyperphosphatemia in CKD can cause a decrease in vitamin D synthesis, which will result in hypocalcaemia, and elevated parathyroid hormone level (PTH).[@b67-ijnrd-12-019],[@b69-ijnrd-12-019],[@b70-ijnrd-12-019] Elevated PTH, in turn, has been shown to directly inhibit erythropoiesis, induce hemolysis, and cause bone marrow fibrosis in CKD.[@b71-ijnrd-12-019]--[@b73-ijnrd-12-019] Although serum PTH levels were not ascertained in our study, the mechanism underlying serum phosphorous, calcium, and anemia in CKD is still unclear.

In this study angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) predicted anemia; this finding is in agreement with previous studies.[@b74-ijnrd-12-019]--[@b76-ijnrd-12-019] The mechanism of action of ACEI and ARBs and their effect on hemoglobin levels in patients with kidney disease is still not well established. Possible mechanisms include interference with production of erythropoietin,[@b75-ijnrd-12-019] modulation of multiple factors interacting with erythroid marrow progenitor;[@b77-ijnrd-12-019] another mechanism may be that angiotensin 2 may increase the proliferation of erythroid progenitors, but not the progenitor of other cell lines, and ARB completely abolishes this effect. All these observations may suggest a possible inhibitory effect of these medications on the bone marrow.[@b75-ijnrd-12-019],[@b77-ijnrd-12-019] Further research is required to establish the exact mechanism of action of these medications.

In conclusion, we found that almost half of CKD participants were anemic which confirms that anemia is a leading comorbidity among CKD patients in Johannesburg. Also, the risk of anemia did not increase linearly with increasing degrees of renal deterioration, as was previously observed by other workers. Thus, CKD staging alone may not be appropriate for screening and monitoring of anemia. In addition, DM and calcium levels were strong predictors of anemia among CKD patients. Our study therefore highlights the need for personalized risk-based prevention and treatment strategies for anemia among CKD patients in low resource settings like ours. The relationship between the severity of kidney deterioration and anemia still needs further evaluation.

This study is not without limitations. Firstly, the cross-sectional design of the study limits us from being able to demonstrate causality between anemia and stages of CKD. As only one set of hemoglobin results was determined, trends and fluctuations in hemoglobin could not be monitored. Secondly, our study may not be generalizable to South African CKD patients, since the study was conducted in an urban setting of South Africa. Thirdly, we did not evaluate serum folate and vitamin B12 levels of our participants which might give more insight on the the nutritional status of the participants. Furthermore, vitamin D and PTHs were not evaluated in this study. Drug history of chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) was not elicited. However, CKD patients in the hospital are generally counseled to avoid NSAIDs, since it can further worsen kidney function. Patients on oral iron and ESA therapy were excluded this study, which could affect the true prevalence of anemia in the studied population. Thus, we were unable to adequately stratify our patients by nutritional status. Despite these limitations, this study has contributed to the existing evidence on the prevalence of anemia across CKD stages in pre-dialysis CKD patients.

Supplementary materials
=======================

###### 

Distribution of anemia and its parameters among different stages of chronic kidney disease in mixed race South Africans

                                Stage I     Stage II    Stage IIIa   Stage IIIb   Stage IV   Stage V     Total (n=258)   *P*-value
  ----------------------------- ----------- ----------- ------------ ------------ ---------- ----------- --------------- ----------------------------------------------------
  Anemia status, n (%)                                                                                                   
   Anaemic                      0 (0.0)     3 (100)     2 (66.7)     2 (50.0)     4 (80.0)   0 (0.0)     11 (55.0)       0.063
   Non-anemic                   1 (100.0)   0 (0.0)     1 (37.3)     2 (50.0)     1 (20.0)   4 (100.0)   9 (45.0%)       
  Hb (g/dL), mean ± SD          12.5±0.57   14.3±0.51   12.1±2.8     11.7±0.8     12.9±2.7   10.0±1.64   12.2±2.2        0.155[a](#tfn14-ijnrd-12-019){ref-type="table-fn"}
  MCV (fL), mean ± SD           90.4±0.42   90.6±0.15   91.5±7.4     84.8±10.7    90.0±5.9   91.2±3.1    89.6±6.1        0.23[a](#tfn14-ijnrd-12-019){ref-type="table-fn"}
  MCH (pg), mean ± SD           32.1±0.7    29.3±0.4    29.1±1.8     27.0±4.7     29.7±2.6   27.5±1.8    28.9±2.8        0.33[a](#tfn14-ijnrd-12-019){ref-type="table-fn"}
  MCHC, mean ± SD               30.7±1.2    32.4±1.0    31.7±1.5     31.8±3.0     32.5±1.2   31.3±1.2    31.8±1.7        0.394[a](#tfn14-ijnrd-12-019){ref-type="table-fn"}
  CRP (mg/L), mean ± SD         10.0±0.0    10.0±0.0    18±13.9      18±14.7      15.8±8.6   17.5±6.8    15.5±9.1        0.179[a](#tfn14-ijnrd-12-019){ref-type="table-fn"}
  CRP groups, n (%)                                                                                                      
   Inflammation (CRP ≥10)       0 (0.0)     0 (0.0)     1 (33.3)     2 (50.0)     2 (40.0)   3 (75.0)    8 (36.1)        0.496[b](#tfn15-ijnrd-12-019){ref-type="table-fn"}
   No inflammation (CRP \<10)   2 (100.0)   3 (100.0)   2 (66.7)     2 (50.0)     3 (60.0)   1 (25.0)    13 (61.9)       

**Notes:**

ANOVA;

Fisher's exact test;

Pearson's chi-squared test.

**Abbreviations:** CRP, C-reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume.

###### 

Distribution of anemia and its parameters among different stages of chronic kidney disease in Indian/Asian South Africans

                               Stage I     Stage II    Stage IIIa   Stage IIIb   Stage IV    Stage V    Total (n=258)   *P*-value
  ---------------------------- ----------- ----------- ------------ ------------ ----------- ---------- --------------- ----------------------------------------------------
  Anemia status, n (%)                                                                                                  
   Anemic                      4 (80.4)    2 (100.0)   1 (50.0)     5 (100)      4 (100.0)   2 (50.0)   18 (81.8%)      0.26
   Non-anemic                  1 (20.0)    0 (0.0)     1 (50.0)     0 (0.0)      0 (0.0)     2 (50.0)   4 (18.2%)       
  Hb (g/dL), mean ± SD         12.8±1.7    14.7±1.4    12.7±1.2     13.3±0.9     14.4±1.4    11.5±3.7   13.1±2.1        0.40[a](#tfn18-ijnrd-12-019){ref-type="table-fn"}
  MCV (fL), mean ± SD          90.7±1.6    90.9±3.5    91.2±5.7     91.8±8.6     90.5±11.8   87.5±4.1   90.0±8.7        0.98[a](#tfn18-ijnrd-12-019){ref-type="table-fn"}
  MCH (pg), mean ± SD          30.5±0.6    22.1±6.6    28.7±2.1     27.1±2.2     27.7±1.9    29.3±2.7   28.0±3.2        0.024[a](#tfn18-ijnrd-12-019){ref-type="table-fn"}
  MCHC, mean ± SD              33.5±0.6    32.2±2.7    32.6±1.1     31.5±0.7     32.7±1.6    32.4±0.5   32.4±1.2        0.28[a](#tfn18-ijnrd-12-019){ref-type="table-fn"}
  CRP (mg/L), mean ± SD        15.8±12.9   14.5±6.4    15.5±7.8     15.6±5.9     11.3±2.5    10.5±1.0   13.8±7.1        0.179[a](#tfn18-ijnrd-12-019){ref-type="table-fn"}
  CRP groups, n (%)                                                                                                     
   Inflammation (CRP ≥10)      1 (20.0)    1 (50.0)    1 (50.0)     4 (80.0)     1 (25.0)    1 (25.0)   9 (40.9)        0.411[b](#tfn19-ijnrd-12-019){ref-type="table-fn"}
   No inflammation (CRP\<10)   4 (80.0)    1 (50.0)    1 (50.0)     1 (50.0)     3 (75.0)    3 (75.0)   13 (59.1)       

**Note:**

ANOVA;

Fisher's exact test;

Pearson's chi-squared test.

**Abbreviations:** CRP, C-reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume.

###### 

Correlation between hemoglobin levels and glomerular filtration rates among chronic kidney disease patients in Johannesburg by ethnicity and gender

  Factor           Correlation coefficient (r)   *P*-value
  ---------------- ----------------------------- -----------
  **Overall**      0.334                         \<0.001
  **Ethnicity**                                  
  Blacks           0.3471                        \<0.001
  Whites           0.4777                        0.0005
  Mixed            0.4720                        0.0413
  Indians/Asians   0.3532                        0.1643
  **Gender**                                     
  Male             0.4722                        \<0.001
  Female           0.2841                        0.0002
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###### 

Sociodemographic and clinical characteristics of the study population by anemia status

  Variable                                         Anemic         Non-anemic                                                                                                           
  ------------------------------------------------ -------------- --------------- -------------- ------------- ------------- -------------- ------------- ------------- -------------- -------------
  **Age (years) (mean ± SD)**                      52.40±14.0     68.39±15.4      64.11±13.7     63.25±15.2    **\<0.001**   52.90±14.6     60.41±13.3    55.45±12.6    62.11±17.6     **0.0099**
  \<50                                             45 (37.19)     3 (16.67)       1 (11.11)      1 (25.00)     0.157         63 (45.99)     6 (17.65)     2 (18.18)     3 (16.67)      **0.001**
  ≥50                                              76 (62.81)     15 (83.33)      8 (88.89)      3 (75.00)     74 (54.01)    28 (82.35)     9 (81.82)     15 (83.33)                   
  \<25                                             3 (2.48)       0 (0.0)         0 (0.0)        0 (0.0)       **0.009**     3 (2.19)       0 (0.0)       1 (9.09)      1 (5.56)       0.062
  25--34                                           12 (9.92)      0 (0.0)         0 (0.0)        0 (0.0)       10 (7.30)     2 (5.88)       0 (0.0)       1 (5.56)                     
  35--44                                           17 (14.05)     1 (5.56)        1 (11.11)      1 (25.00)     26 (18.98)    1 (2.94)       1 (9.09)      1 (5.56)                     
  45--54                                           28 (23.14)     2 (11.11)       0 (0.00)       0 (0.00)      37 (27.01)    7 (20.59)      1 (9.09)      2 (11.11)                    
  55--64                                           42 (34.71)     4 (22.22)       4 (44.44)      0 (0.00)      27 (19.71)    11 (20.59)     5 (9.09)      3 (16.67)                    
  ≥65                                              19 (15.70)     11 (61.11)      4 (44.44)      3 (75.00)     34 (24.82)    13 (38.24)     3 (27.27)     10 (55.56)                   
  **Gender**                                                                                                                                                                           
  Male                                             58 (47.93)     10 (55.56)      3 (33.33)      3 (75.00)     0.508         76 (55.47)     20 (58.82)    3 (27.27)     10 (55.56)     0.307
  Female                                           63 (52.07)     8 (44.44)       6 (66.67)      1 (25.00)     61 (44.53)    14 (41.18)     8 (72.73)     8 (44.44)                    
  **Educational attainment**                                                                                                                                                           
  None                                             54 (44.63)     1 (5.56)        0 (0.00)       0 (0.00)      **\<0.001**   69 (50.36)     1 (2.94)      0 (0.00)      0 (0.00)       **\<0.001**
  Primary                                          42 (34.71)     0 (0.00)        4 (44.44)      1 (25.00)     39 (28.47)    2 (5.88)       4 (36.36)     2 (11.11)                    
  High school                                      20 (16.53)     5 (27.78)       2 (22.22)      3 (75.00)     23 (16.79)    11 (32.35)     5 (45.45)     11 (61.11)                   
  Tertiary                                         5 (4.13)       12 (66.67)      3 (33.33)      0 (0.00)      6 (4.38)      20 (58.82)     2 (18.18)     5(27.78)                     
  **Occupation**                                                                                                                                                                       
  Civil servant                                    27 (22.31)     2 (11.11)       2 (22.22)      1 (25.00)     **0.012**     29 (21.17)     11 (32.35)    1 (9.09)      2 (11.11)      **\<0.001**
  Unemployed                                       60 (49.59)     3 (16.67)       2 (22.22)      2 (50.00)     68 (49.64)    4 (11.76)      3 (27.27)     2 (11.11)                    
  Retired                                          24 (19.83)     12 (66.67)      3 (33.33)      1 (25.00)     23 (16.79)    16 (47.06)     4 (36.36)     11 (61.11)                   
  Student                                          4(3.31)        0 (0.00)        0 (0.00)       0 (0.00)      6 (4.38)      0 (0.00)       1 (9.09)      2 (11.11)                    
  Trading/private employee                         6 (4.96)       1 (5.56)        2 (22.22)      0 (0.00)      11 (8.03)     3 (8.82)       2 (18.18)     1 (5.56)                     
  **Smoking status**                                                                                                                                                                   
  Smoker                                           0 (0.00)       0 (0.00)        0 (0.00)       0 (0.00)      50 (36.50)    25 (73.53)     6 (54.55)     11 (61.11)    **0.001**      
  Non-smoker                                       121 (100.00)   18 (100.00)     9 (100.00)     4 (100.00)    87 (63.50)    9 (26.47)      5 (45.45)     7 (38.89)                    
  **ACE-I/ARB**                                                                                                                                                                        
  Yes                                              64 (52.89)     14 (77.78)      6 (66.67)      4 (100.00)    0.061         2 (1.46)       1 (2.94)      2 (18.18)     1 (5.56)       **0.027**
  No                                               57 (47.11)     4 (22.22)       3 (33.33)      0 (0.00)      135 (98.54)   33 (97.06)     9 (81.82)     17 (94.44)                   
  **CKD stages**                                                                                                                                                                       
  Stage I                                          9 (7.44)       1 (5.56)        1 (11.11)      1 (25.00)     0.309         14 (10.22)     1 (2.94)      0 (0.00)      4 (22.22)      0.223
  Stage II                                         8 (6.61)       0 (0.00)        0 (0.00)       0 (0.00)      26 (18.98)    3 (8.82)       3 (27.27)     2 (11.11)                    
  Stage IIIa                                       7 (5.79)       1 (5.56)        1 (11.11)      1 (25.00)     25 (18.25)    8 (23.53)      2 (18.18)     1 (5.56)                     
  Stage IIIb                                       13 (10.74)     6 (33.33)       2 (22.22)      0 (0.00)      39 (28.47)    10 (29.41)     2 (18.18)     5 (27.78)                    
  Stage IV                                         31 (25.62)     6 (33.33)       1 (11.11)      0 (0.0)       28 (20.44)    12 (35.29)     4 (36.36)     4 (22.22)                    
  Stage V                                          53 (43.80)     4 (22.22)       4 (44.44)      2 (50.00)     5 (3.65)      0 (0.0)        0 (0.0)       2 (11.11)                    
  Systolic blood pressure (mm Hg \[mean ± SD\])    141.54±24.5    151.40±26.9     151.67±25.9    136.42±15.0   **0.3998**    145.42±21.1    141.86±15.9   146.91±30.5   135.89±20.1    0.3009
  Diastolic blood pressure (mm Hg \[mean ± SD\])   80.57±16.3     80.50±12.0      82.78±17.4     76±4.5        **0.919**     82.91±14.7     74.57±9.8     79.64±14.3    76.61±11.57    **0.0329**
  Body mass index, kg/m^2^ (mean ± SD)             29.34±6.8      29.25±10.4      28.88±4.5      24.90±3.5     **0.6574**    30.39±5.9      31.93±8.6     28.81±7.5     24.60±4.2      **0.0018**
  Serum creatinine, µmol/L (mean ± SD)             511.67±518.6   270.72±190.31   303.89±217.2   422±366.6     **0.1629**    179.59±101.0   152.79±57.0   160.09±85.9   219.16±137.4   0.1254
  Serum urea, µmol/L (mean ± SD)                   21.57±15.0     14.36±6.1       17.62±7.0      14.93±7.0     **0.1551**    11.45±11.2     9.95±4.2      10.31±6.3     11.76±4.5      0.8469
  TSAT (mean ± SD)                                 19.36±32.0     17.06±8.3       22±9.9         17.25±10.1    **0.9769**    20.18±7.7      23.62±7.4     18.36±7.8     20.55±4.9      0.0756
  Ferritin, ng/dL (mean ± SD)                      210.69±23.6    148.8±13.7      269.44±21.4    147.25±80.9   **0.5301**    116.20±80.5    150.41±70.2   103.45±82.7   153.33±71.2    **0.0392**
  GFR, mL/min/1.73[@b2-ijnrd-12-019] (mean ± SD)   30.58±38.5     26±14.3         21.38±14.4     24±26.3       **0.8588**    50.53±28.6     38.15±12.8    37.73±18.1    32.36±16.4     **0.0064**
  C-reactive protein, mg/L (mean ± SD)             34.05±55.6     43.06±55.4      18.33±9.2      10±0          **0.5571**    13.33±9.0      21.15±53.5    13.64±9.2     14.67±7.6      0.3827

**Notes:** Data shown as n (%) unless otherwise specified. Bold *P*-values were statistically significant.

**Abbreviations:** ACE-I, angiotensin-converting enzyme inhibitor use; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; GFR, glomerular filtration rate; IQR, interquartile range; TSAT, transferrin saturation.

###### 

Distribution of anemia and its parameters among different stages of chronic kidney disease in black South Africans

                                Stage I     Stage II    Stage IIIa   Stage IIIb   Stage IV    Stage V     Total (n=258)   *P*-value
  ----------------------------- ----------- ----------- ------------ ------------ ----------- ----------- --------------- ------------------------------------------------------
  Anemia status, n (%)                                                                                                    
   Anemic                       9 (39.1)    8 (23.5)    7 (21.9)     13 (25.0)    31 (52.5)   53 (91.4)   121 (46.9%)     \<0.001[a](#tfn3-ijnrd-12-019){ref-type="table-fn"}
   Non-anemic                   14 (60.9)   26 (76.5)   25 (78.1)    39 (75%)     28 (47.5)   5 (8.6%)    137 (53.1%)     
  Hb (g/dL), mean ± SD          12.8±2.3    13.6±2.5    13.8±1.9     13.3±2.0     12.1±2.3    9.5±2.3     12.2±2.7        0.0001[b](#tfn4-ijnrd-12-019){ref-type="table-fn"}
  MCV (fL), mean ± SD           87.7±5.7    91.0±6.9    88.6±6.2     89.2±5.6     85.1±6.2    86.8±6.1    87.8±6.3        0.0002[b](#tfn4-ijnrd-12-019){ref-type="table-fn"}
  MCH (pg), mean ± SD           28.9±2.2    29.8±2.4    29.1±2.2     28.9±2.1     27.5±2.7    27.9±2.3    28.5±2.5        0.0001[b](#tfn4-ijnrd-12-019){ref-type="table-fn"}
  MCHC, mean ± SD               31.9±3.2    32.8±1.7    32.9±0.9     32.5±1.5     32.3±1.6    31.9±2.2    32.4±1.9        0.15[b](#tfn4-ijnrd-12-019){ref-type="table-fn"}
  CRP (mg/L), mean ± SD         10.8±1.5    21.9±5.0    10.8±2.7     13.8±8.4     15.5±10.2   51.3±6.6    23.0±3.9        \<0.0001[b](#tfn4-ijnrd-12-019){ref-type="table-fn"}
  CRP groups, n (%)                                                                                                       
   Inflammation (CRP ≥10)       6 (26.1)    7 (20.6)    3 (9.4)      16 (30.8)    25 (42.4)   50 (86.2)   107 (41.5)      \<0.0001[c](#tfn5-ijnrd-12-019){ref-type="table-fn"}
   No inflammation (CRP \<10)   17 (73.9)   27 (79.4)   29 (90.6)    36 (69.2)    34 (57.6)   8 (13.8)    151 (58.5)      

**Notes:**

Pearson's chi-squared test;

ANOVA;

Fisher's exact test.

**Abbreviations:** CRP, C-reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume.

###### 

Post hoc Bonferroni pairwise test of distribution of anemia and its parameters among different stages of CKD in black South Africans

  Parameter   Post hoc Bonferroni test across stages
  ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hb          There was a statistically significant decrease in mean Hb levels between stage V and stages I, II, IIIa, IIIb, and IV (*P*-value \<0.001)
  MCV         There was a statistically significant difference in MCV between stage IV and stages II and IIIb (stage IV *vs* stage II, *P*-value \<0.001; stage IV *vs* stage IIIb, *P*-value =0.009); the mean MCV of stage V CKD was also statistically different from stage II (stage V *vs* stage II, *P*-value =0.021)
  MCH         There was a statistically significant difference in mean MCH between stage IV and stages II, IIIa, and IIIb (stage IV vs stage II, *P*-value \<0.001; stage IV *vs* stage IIIa, *P*-value =0.042; stage IV *vs* stage IIIb, *P*-value =0.027). Also, the mean MCH of stage V CKD was statistically different from stage II (stage V *vs* stage II, *P*-value =0.003)
  CRP         The mean CRP levels among stage V CKD patients were statistically different from those of stages I (*P*-value =0.030), IIIa (*P*-value =0.008), IIIb (*P*-value =0.005), and IV (*P*-value =0.003)

**Abbreviations:** CKD, chronic kidney disease; CRP, C-reactive protein; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume.

###### 

Distribution of anemia and its parameters among different stages of chronic kidney disease in white South Africans

                                Stage I     Stage II    Stage IIIa   Stage IIIb   Stage IV    Stage V     Total (n=258)   *P*-value
  ----------------------------- ----------- ----------- ------------ ------------ ----------- ----------- --------------- ----------------------------------------------------
  Anemia status, n (%)                                                                                                    
   Anemic                       1 (50.0)    0 (0.0)     1 (11.1)     6 (37.5)     6 (33.3)    4 (100.0)   18 (34.6%)      0.036
   Non-anemic                   1 (50.0)    3 (100.0)   8 (88.9)     10 (62.5)    12 (66.7)   0 (0.0)     34 (65.4%)      
  Hb (g/dL), mean ± SD          12.6±0.99   16.4±0.85   13.3±2.0     13.3±2.0     13.0±2.3    8.1±0.79    13.0±2.5        0.0001[a](#tfn8-ijnrd-12-019){ref-type="table-fn"}
  MCV (fL), mean ± SD           90.7±1.6    90.9±3.5    91.2±5.7     91.8±8.6     90.5±11.8   87.5±4.1    90.8±8.7        0.979[a](#tfn8-ijnrd-12-019){ref-type="table-fn"}
  MCH (pg), mean ± SD           31.7±1.6    29.8±0.38   30.1±2.1     29.7±3.1     29.8±3.0    27.4±0.17   29.7±2.7        0.51[a](#tfn8-ijnrd-12-019){ref-type="table-fn"}
  MCHC, mean ± SD               30.7±0.8    32.8±1.0    32.5±0.9     31.3±2.5     32.1±1.2    31.4±1.6    31.8±1.7        0.394[a](#tfn8-ijnrd-12-019){ref-type="table-fn"}
  CRP (mg/L), mean ± SD         10.0±0.0    17.3±6.4    45.6±10.4    17.4±16.4    20.4±2.5    91.3±9.7    28.7±5.5        0.179[a](#tfn8-ijnrd-12-019){ref-type="table-fn"}
  CRP groups, n (%)                                                                                                       
   Inflammation (CRP ≥10)       0 (0.0)     2 (66.7)    4 (44.4)     6 (37.5)     7 (38.9)    3 (75.0)    22 (42.3)       0.619[b](#tfn9-ijnrd-12-019){ref-type="table-fn"}
   No inflammation (CRP \<10)   2 (100.0)   1 (33.3)    5 (55.6)     10 (62.5)    11 (61.1)   1 (25.0)    30 (57.7)       

**Notes:**

ANOVA;

Fisher's exact test;

Pearson's chi-squared text.

**Abbreviations:** CRP, C-reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume.

###### 

Predictors of anemia among chronic kidney disease patients

  Variable                       OR      95% CI          *P*-value   Adjusted OR   95% CI          *P*-value
  ------------------------------ ------- --------------- ----------- ------------- --------------- -----------
  **GFR (mL/min/1.73 m^2^)**                                                                       
  Stage I                        1.00    Reference       Reference   1.00          Reference       Reference
  Stage II                       0.37    0.13--1.07      0.067       0.20          0.05--0.81      0.024
  Stage III                      0.53    0.23--1.22      0.138       0.17          0.05--0.54      0.003
  Stage IV                       1.25    0.54--2.90      0.598       0.66          0.21--2.08      0.479
  Stage V                        14.25   4.93--41.29     \<0.001     3.83          0.95--15.39     0.059
  **Age (years**)                                                                                  
  \<50                           1.00    Reference       Reference   1.00          Reference       Reference
  ≥50                            1.20    0.77--1.87      0.425       2.33          1.05--5.16      0.037
  **Race**                                                                                         
  Blacks                         1.00    Reference       Reference   1.00          Reference       Reference
  Indian/Asian                   0.60    0.32--1.12      0.106       0.04          0.01--0.28      0.001
  Mixed                          0.93    0.37--2.31      0.870       0.45          0.09--2.36      0.347
  White                          0.25    0.08--0.76      0.015       0.41          0.14--1.23      0.111
  **Gender**                                                                                       
  Male                           1.00    Reference       Reference   1.00          Reference       Reference
  Female                         1.26    0.83--1.93      0.280       0.74          0.38--1.46      0.388
  **History of DM**                                                                                
  No                             1.00    Reference       Reference   1.00          Reference       Reference
  Yes                            2.07    1.32--3.25      0.002       2.06          1.00--4.25      0.050
  **History of hypertension**                                                                      
  No                             1.00    Reference       Reference   1.00          Reference       Reference
  Yes                            0.90    0.30--2.74      0.852       --            --              --
  **Hypoalbuminemia (g/L**)                                                                        
  No (\>35)                      1.00    Reference       Reference   1.00          Reference       Reference
  Yes (≤35)                      5.33    2.61--10.89     \<0.001     3.24          1.10--9.53      0.033
  **Hypocalcemia**                                                                                 
  No (\>2.5)                     1.00    Reference       Reference   1.00          Reference       Reference
  Yes (≤2.5)                     6.52    3.55--11.98     \<0.001     --            --              --
  **Hyperphosphatemia**                                                                            
  No (\<1.45 mmol/L)             1.00    Reference       Reference   1.00          Reference       Reference
  Yes (\>1.45 mmol/L)            1.40    0.63--3.14      0.227       --            --              --
  **Dyslipidemia**                                                                                 
  No                             1.00    Reference       Reference   1.00          Reference       Reference
  Yes                            1.25    0.58--2.68      0.568       --            --              --
  **TSAT (%**)                                                                                     
  \>20                           1.00    Reference       Reference   1.00          Reference       Reference
  \<20                           0.38    0.24--0.60      \<0.001     0.40          0.19--0.83      0.014
  **CRP (mg/L**)                                                                                   
  Normal (CRP \<10)              1.00    Reference       Reference   1.00          Reference       Reference
  Inflammation (CRP ≥10)         3.93    2.51--6.16      \<0.001     1.16          0.57--2.34      
  **ACE-I/ARB**                                                                                    
  No                             1.00    Reference       Reference   1.00          Reference       Reference
  Yes                            44.46   18.55--106.53   \<0.0001    75.68         21.34--268.35   \<0.001
  **Serum ferritin**                                                                               
  \>100                          1.00    Reference       Reference   1.00          Reference       Reference
  ≤100                           1.50    0.98--2.31      0.065       --            --              --
  **Obesity (BMI, kg/m^2^**)                                                                       
  Normal (18.5--24.9)            1.00    Reference       Reference   1.00          Reference       Reference
  Obese (25--34.9)               0.68    0.25--0.98      0.195       --            --              --
  Morbid obesity (\>35)          0.78    0.28--1.06      0.391       --            --              --
  **Serum creatinine (mg/dL**)                                                                     
  \<2.5                          1.00    Reference       Reference   1.00          Reference       Reference
  \>2.5                          5.58    3.50--8.88      \<0.0001    --            --              --

**Notes:** Multivariable model corrected for stage of the disease, age, gender, history of DM, hypoalbuminemia, ACE-I/ARB use. Hosmer--Lemeshow chi-square =204.89 and its *P*-value =0.9939.

**Abbreviations:** ACE-I, angiotensin-converting enzyme inhibitor use; ARB, angiotensin receptor blocker; BMI, body mass index; CRP, C-reactive protein; DM, diabetes mellitus; GFR, glomerular filtration rate; OR, odds ratio; TSAT, transferrin saturation.
